Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
TherapeuticsMD (NASDAQ: TXMD) reports 2025 results, weighs strategic options
TherapeuticsMD (NASDAQ: TXMD) reported its full-year 2025 financial results, showing a net loss of $(0.7) million and license revenues of $3.0 million, an increase of 71.6% from 2024. The company, which transitioned to a pharmaceutical royalty business in December 2022, is actively evaluating strategic alternatives including mergers, acquisitions, or asset sales. TherapeuticsMD emphasizes risks associated with licensee performance, ongoing disputes, and its ability to maintain its Nasdaq listing.